Preclinical results support the use of CEA-IL2v for combination immunotherapy with ADCC-competent or -enhanced antibodies of the IgG1 isotype, T cell bispecific antibodies that rely on CD8+ T effector cells and also with PD-L1 checkpoint blockade in immunogenic tumor. The gene discussed is CD8A; the disease is neoplasm.